Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 10, 2023
Deals
May 10 Quick Takes: Bicycle in third radiopharma deal of year
Plus: 15% weight reduction for Boehringer, Zealand Phase II asset and updates from Aviko, DiogenX, Syneos, OliX and more
BioCentury | May 5, 2023
Product Development
May 5 Quick Takes: Argenx’s Vyvgart tops 1Q23 consensus sales
Plus: Protalix/Chiesi therapy for Fabry wins EU approval, and updates from FibroGen, NGM and more
BioCentury | Aug 30, 2022
Product Development
Aug. 30 Quick Takes: Lumakras meets in lung cancer Phase III
Plus vopratelimab miss weighs on Jounce and updates from MedGenome, Sangamo and more
BioCentury | Apr 5, 2022
Politics, Policy & Law
April 4 Quick Takes: University of California continues CRISPR IP fight
Plus Protalix gains on Fabry data and updates from Alnylam, Curis, Gilead, BMS
BioCentury | Mar 8, 2022
Emerging Company Profile
Congruence: identifying protein folding correctors
Montreal-based newco is cataloging properties of misfolded proteins and building a virtual chemical library to screen for stabilizers
BioCentury | Nov 5, 2021
Product Development
Sangamo’s turn to gene therapy scores early win in Fabry
But the veteran biotech is not abandoning its zinc finger technology
BioCentury | Oct 23, 2021
Discovery & Translation
ESGCT preclinical roundup; plus Generation, Pionyr and more
BioCentury’s roundup of translational news
BioCentury | Oct 7, 2021
Product Development
Fabry disease’s five-year prospects look up
Comparing the profiles of up-and-coming therapies for Fabry disease
BioCentury | May 12, 2020
Product Development
May 11 Quick Takes: Genfit’s elafibranor misses in NASH Phase III; plus AstraZeneca, Merck, Protalix and TolerogenixX
Items per page:
1 - 10 of 231